Synbiotic Formulations for Gut Health Latest Research Insights

Oral nutritional composition for improving digestive health and reducing inflammation in humans. The composition contains specific amounts of gold kiwifruit powder, heat-treated Lactobacillus plantarum, Bacillus subtilis, and Bacillus coagulans. Administering these ingredients orally can reduce constipation, improve cholesterol levels, reduce bacterial vaginosis symptoms, lower inflammation from gingivitis, prevent hepatic encephalopathy in cirrhosis, and boost immune response.

Source

Enhancing the efficacy of nutraceuticals, dietary supplements, and drugs by replacing live probiotics with inactivated paraprobiotics along with their postbiotics. Paraprobiotics are dead bacteria that still contain their postbiotic metabolic byproducts. The paraprobiotics are used instead of live probiotics to avoid issues like drug resistance, pathogenic plasmid transfer, and dysbiosis. The paraprobiotics are inactivated by heat or other methods. The postbiotics are the soluble growth end products released by bacteria during growth. Adding paraprobiotics and postbiotics to nutraceuticals, supplements, and drugs can improve their preventative or therapeutic effects without requiring higher dosages.

Source

A composition for improving intestinal health containing perilla enzyme-treated product as an effective ingredient and method for producing the same. The composition comprises pear powder treated with a complex enzyme including cellulase, β-glucanase, and xylanase, which solubilizes dietary fiber of pear sludge through an enzymatic reaction, produces dietary fiber rich in hemicellulose, and increases solubility, water retention capacity, oil retention capacity, swelling capacity, and cholesterol adsorption capacity. The composition promotes the growth of beneficial intestinal bacteria and inhibits the growth of harmful bacteria, thereby improving intestinal health and preventing or treating intestinal diseases.

Source

Probiotic compositions and methods comprising bacteria of the genus Rouxiella, particularly Rouxiella badensis, for promoting gut health, preventing gastrointestinal disorders, and enhancing immune function. The probiotic strains exhibit unique characteristics, including acid production, bile salt resistance, and antimicrobial activity, and demonstrate efficacy in animal models of intestinal disease.

Source

A composition for improving gut microbiota composition, comprising a novel lactic acid bacterial strain, Pediococcus acidilactici, and/or extracellular vesicles secreted by said strain. The strain, deposited at NCIMB Ltd. with accession number NCIMB 44102, is isolated from chicken guts and exhibits unique genomic characteristics. The composition can be administered orally and is effective in improving gut health through the interaction of extracellular vesicles with neighboring bacteria.

Source

A method for modulating a microbiome to promote health and prevent disease by identifying beneficial bacterial strains and administering them to a subject in need. The method involves isolating and characterizing beneficial bacterial strains, selecting strains associated with health, and administering them to a subject to modulate the microbiome and promote health. The method can be used to treat a variety of conditions, including obesity, diabetes, inflammatory bowel disease, and allergies, by promoting the growth of beneficial microbes, inhibiting the growth of harmful microbes, or modulating the immune system.

Source

Combination of specific oligosaccharides and Bifidobacterium longum subspecies infantis (B. infantis) to protect infants, young children, and children from enteric pathogens like Salmonella and EPEC. The combination comprises a high level of lacto-N-fucopentaose I (LNFP-I) as a fucosylated human milk oligosaccharide (HMO) along with B. infantis. The high LNFP-I content enhances immune response to bacterial infections and promotes gut health. Administering this combination to infants prevents and inhibits growth of enteric pathogens in their guts.

Source

A novel Lactobacillus helveticus strain, designated as UA881, that exhibits multiple health benefits including improving intestinal permeability, alleviating hyperlipidemia, hypercholesterolemia, and hyperuricemia, relieving intestinal inflammation, activating antioxidant systems, and generating micro-nutrients. The strain, deposited in NITE under accession number NITE BP-03802, can be used to produce a probiotic composition that promotes cardiovascular health, relieves leaky gut syndrome and metabolic disorders, and reduces the risk of gout arthritis.

Source

A synergistic probiotic and oligosaccharide combination for infant gut health, specifically targeting early life intestinal microbial dysbiosis. The composition comprises a unique blend of specific bifidobacterial species and human milk oligosaccharides (HMOs) that interact in a synergistic manner. The bifidobacterial strains, particularly B. bifidum and B. breve, possess extracellular enzymes that degrade specific HMOs, while B. breve strains with beta1,4-galactanase activity facilitate the degradation of galactose-containing HMOs. This combination enables enhanced fermentation and growth of the bifidobacterial strains, particularly in the presence of HMOs, while maintaining the beneficial properties of the oligosaccharides.

Source

Multi-biotic dietary supplements that combine a postbiotic or postbiotic precursor, a probiotic blend, and a prebiotic blend in a single dose. The supplements can be formulated with an inner capsule containing the probiotic and prebiotic blend, and an outer capsule containing the postbiotic or postbiotic precursor. The inner and outer capsules can have different dissolution or degradation rates to optimize delivery of each component to the gastrointestinal tract. The supplements can be designed to improve gut health, digestive health, and immune health by providing a synergistic combination of postbiotics, probiotics, and prebiotics.

Source

Probiotic Lactobacillus strains that improve food component digestibility through enhanced nutritional metabolism. The strains, isolated from dairy products, fruits, and vegetables, exhibit superior digestive capabilities compared to conventional probiotics. The strains achieve this through enhanced hydrolysis of proteins, phenolic compounds, and raffinose, as well as increased bioavailability of these nutrients. The strains are formulated as a dietary supplement for oral administration, with a carrier that maintains their viability and activity.

Source

A probiotic protein complex vitamin comprising immune protein activation factor, complex vitamins, maca powder, panax notoginseng powder, dextrin, and corn starch, with a simultaneous fermentation process of multiple strains. The vitamin formulation is designed to enhance immune function, metabolic pathways, and overall physical fitness, while also promoting gastrointestinal health and preventing diarrhea.

Source

Microbial consortium comprising two or more microorganisms capable of modulating physiological processes in the host, including gut-brain axis, enteric nervous system, and metabolic pathways. The microorganisms produce specific metabolites, such as GABA, that modulate host physiological processes, including serotonin levels, gut barrier function, and inflammatory response. The consortium can be used to treat functional gastrointestinal disorders by enhancing gut health, reducing inflammation, and modulating neurotransmitter activity.

Source

Compositions comprising a probiotic combination of two or more bacterial strains from different species, including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus gasseri, Lactobacillus rhamnosus, and Bifidobacterium lactis, for preventing and treating metabolic syndrome and related disorders. The combination is particularly effective when comprising Lactobacillus gasseri and Bifidobacterium lactis, and has been shown to reduce cholesterol, triglycerides, and waist circumference, while also lowering inflammatory markers.

Source

Probiotic strain that exhibits antibacterial and anti-inflammatory properties against harmful intestinal bacteria, particularly for treating inflammatory bowel diseases like colitis. The strain, Lactobacillus plantarum CLP2001, CLP2002, and CLB0820, has been identified through comprehensive molecular analysis. This strain possesses potent antimicrobial and immunomodulatory effects, with demonstrated efficacy against pathogenic microorganisms and inflammatory cytokines. The strain can be used in food products, particularly as a dietary supplement, to improve intestinal health and prevent colitis-related symptoms.

Source

A synergistic composition and method for treating diseases involving inflammation, infection, allergy, immune dysfunction, or dysbiosis of the intestinal microbiome. The composition combines a prebiotic mix of human milk oligosaccharides, Bifidobacterium strains that consume the prebiotic, and propionate-producing bacteria. Administering this synergistic composition promotes beneficial effects like increasing propionate in the gut, preventing negative health impacts from dysbiosis, and treating diseases associated with inflammation, infection, allergy, or immune dysfunction.

Source

A novel use of Lactobacillus paracasei subsp. paracasei K56 for enhancing intestinal immunity and resistance to bacterial infection. The strain significantly reduces pathogenic bacterial adhesion to intestinal epithelial cells, improves barrier function, and activates intestinal immunity. It can be used in food, pharmaceutical, or feed products to prevent diarrhea and combat bacterial infections.

Source

A composition for improving gut microbiota comprising a specific combination of bacterial species, including Akkermansia muciniphila, Ruminococcus bromii, and Bifidobacterium lactis, which has been shown to increase the abundance of beneficial bacteria, reduce pathogenic bacteria, and increase short-chain fatty acid production in the gut, thereby alleviating gastrointestinal symptoms and promoting overall gut health.

Source

A system for designing personalized microbiome therapeutics and diet based on functions of an individual's microbiome. The system analyzes gut microbiome composition and function to identify dysbiotic states and perturbed metabolic pathways. It generates personalized therapeutic recommendations, including probiotics, prebiotics, and dietary interventions, based on the individual's microbiome profile and functional deficits.

Source

Pumpkin seed protein composition for increasing beneficial intestinal bacteria and reducing harmful bacteria. The composition contains pumpkin seed protein, isolated pumpkin seed protein, hydrolyzed pumpkin seed protein, or concentrated pumpkin seed protein. Administering this composition increases levels of beneficial bacteria like Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium longum, and Bifidobacterium lactis while reducing harmful bacteria like E. coli. This promotes intestinal health.

Source

Food products made from a symbiotic co-culture of fungi and bacteria that provide high protein and fiber content. The co-culture is optimized to grow and produce a pellicle floating on the fermentation broth. The pellicle is harvested, shaped, and processed into food articles. The fungi provide protein and the bacteria contribute fiber, resulting in products with at least 5% protein and 5% fiber by dry weight. The co-culture composition, fermentation conditions, and pellicle harvesting are optimized for high protein and fiber yields.

Source

A Lactobacillus paracasei strain with probiotic potential that can enhance immunity, improve allergies, and tolerate acidic environments. The strain is deposited as GDMCC No. 60960. The strain can be used in food products, dietary supplements, and pharmaceutical compositions.

Source

A probiotic strain of Pediococcus acidilactici that offers enhanced immune system support and antioxidant protection through its unique combination of antimicrobial and antioxidative activities. The strain, Pediococcus acidilactici TAK 589 Coccobest, exhibits broad-spectrum antibacterial and antioxidative properties, making it suitable for use in human health products, animal feed, and food preservation applications. Its lyophilized form can be administered as a probiotic supplement or used as a starter culture in food and beverage production.

Source

Controlling the proliferation of bacteria selected from the group consisting of bacteria of the genus Faecalibacterium, bacteria of the genus Akkermansia, bacteria of the genus Blautia, bacteria of the genus Subdoligranulum, and bacteria of the genus Bilophila. The control includes administering a composition comprising strain A of the genus Blautia, bacteria of the genus Subdoligranulum, and bacteria of the genus Bilophila.

Source

A novel strain of Akkermansia muciniphila bacteria called Amuc-i09 that can grow without mucin in a vegetable media under anaerobic conditions. The Amuc-i09 strain provides a solution to the challenges of culturing Akkermansia bacteria, which typically requires mucin. The strain can be used to create compositions for treating disorders like diabetes and obesity by increasing Akkermansia populations in the gut. It can also be used as a probiotic to improve gut health.

Source

Compositions comprising Akkermansia bacteria or extracts thereof for preventing and treating reward dysregulation disorders, including eating disorders and addiction, by modulating the gut-brain axis and reducing systemic and neuroinflammation.

Source

Pet food compositions containing probiotics and psyllium that improve gut health and microbiome in animals. The compositions include a probiotic strain like Enterococcus and psyllium fiber. Administering this combination to animals improves gut microbiota by increasing beneficial bacteria like Lactobacillus and Bifidobacterium while decreasing pathogenic bacteria like Clostridium perfringens. The psyllium ferments in the gut to provide a suitable environment for the probiotics.

Source

Therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health. The compositions are advantageous in being suitable for safe administration to humans and other mammalian subjects and are efficacious in numerous gastrointestinal diseases, disorders and conditions and in general nutritional health.

Source

A combination of two probiotic strains, Lacticaseibacillus paracasei S38 and Bacillus coagulans BC198, that effectively improve body compositions by aiding weight loss and reducing body fat. The strains, isolated from human feces and green malt, respectively, have synergistic effects when administered together at lower doses compared to individually. This combination helps inhibit lipogenesis, reduce appetite, increase butyric acid production, and promote beneficial gut bacteria like Akkermansia muciniphila and Ruminococcaceae. It can be used as a probiotic supplement, food, or medication to aid weight loss and body composition improvement.

Source

A composition containing three lactic acid bacterial strains, Lactobacillus rhamnosus MP108, Bifidobacterium longum subsp. infantis BLI-02, and Bifidobacterium animalis subsp. lactis BB-115, for improving gastrointestinal barrier function, alleviating gastrointestinal barrier dysfunction-associated disorders, and inhibiting growth of enteric pathogenic bacteria. The composition is administered orally or parenterally and can be formulated into various dosage forms, including food products and pharmaceutical compositions.

Source

Compositions comprising live microbial populations for treating and preventing immune system disorders and conditions related to inflammation, including pathogen-assisted conditions and those independent of pathogens. The compositions comprise specific combinations of bacteria, including Lactobacillus brevis, Lactococcus lactis, Bacillus velenzensis, and Lactobacillus harbinensis, which have been identified for their immune-modulating properties. The compositions can be administered orally in various forms, including capsules, tablets, and powders, and can be formulated with enteric coatings to protect the microbes from stomach acid.

Source

Compositions and methods for treating disorders of the gastrointestinal tract, such as Clostridium difficile associated diarrhea (CDAD), type 2 diabetes, obesity, irritable bowel disease (IBD), colonization with pathogens or pathobionts, and infection with drug-resistant pathogens or pathobionts. The compositions contain a plurality of isolated bacteria or a purified bacterial preparation capable of forming a network ecology. The network ecology is a specific combination of bacterial strains that work together to restore and enhance microbiota functions.

Source

Probiotic, prebiotic, and synbiotic compositions to enhance immunity and prevent/treat pathogen infections, like respiratory viruses. The compositions contain specific strains of Bifidobacterium bacteria (Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum) along with prebiotics like xylooligosaccharide, galactooligosaccharide, and corn dietary fiber. Administering these compositions can assist in preventing and treating pathogen infections, enhancing pathogen therapy, improving immunity, and balancing gut microbiota.

Source

A fiber mix formulation for promoting a healthy gut microbiome by restoring a balanced gut bacteria composition. The formulation contains a specific ratio of bran, inulin, and digestion resistant maltodextrin fibers. The mix has a 1:1:1 to 4:1:1 fiber ratio, with 5-10% inulin. It promotes acetate and butyrate producers while inhibiting pathogens. The uniform particle size between 150-300um allows consistent fermentation. Administering this fiber mix can increase beneficial bacteria and improve gut health.

Source

A composition for treating dysbiosis-related conditions comprising two purified bacterial populations: a long-term engrafting population and a transient engrafting population. The long-term population includes bacteria with specific 16S rDNA sequences, while the transient population includes bacteria with specific functional features such as anti-inflammatory activity, bile acid production, and epithelial integrity restoration. The composition is designed to provide a consistent and stable product for treating conditions like inflammatory bowel disease and cancer.

Source

Fusion Weissella bacterium that can improve the digestive ability of dogs and inhibit common pathogenic bacteria that cause diarrhea. The strain improves the digestive ability of dogs and inhibits common pathogenic bacteria that cause diarrhea. The strain provides good resistance to antibiotics, has a significant inhibitory effect on common diarrhea-causing pathogens, has the ability to assist digestion, and is non-toxic when taken orally.

Source

Artificial intelligence-based method for designing functional microbiomes that improves the efficacy of target probiotic strains. The method uses a database of intestinal microbial strains and their interactions to predict a group of microorganisms that can enhance the growth, activity, stability, and colonization of specific probiotic strains in the human gut.

Source

Probiotic composition that prevents pathogen growth in poultry GI tracts. The composition includes a mixture of probiotics with prebiotics, including but not limited to: fructooligosaccharides (derived from natural or synthetic source such as onions, chicory, asparagus, artichokes, etc.), xylooligosaccharides (derived from natural or synthetic sources such as sugar cane, bamboo, soybeans and other vegetables as well as fruits), and galactooligosaccharides (derived from natural or synthetic sources such as legumes, dairy products, or root vegetables).

Source

A microbiota recovery composition for treating antibiotic-induced gut microbiota imbalance, comprising live biotherapeutic products (LBPs) that selectively target and restore depleted bacterial populations and functions, including short-chain fatty acid production, pathogen inhibition, and polysaccharide degradation, to prevent diarrhea and other adverse effects following antibiotic treatment. The composition is formulated with a combination of known and novel bacterial strains, including Bifidobacterium and Lactobacillus species, that are specifically selected based on their functional properties and ability to recover from antibiotic-induced depletion.

Source

Composition comprising pasteurized Akkermansia muciniphila for the treatment or prevention of gut contractility disorders, particularly duodenal contraction amplitude disorder, wherein the Akkermansia is administered in an amount from 1.10^8 to 5.10^10 cells per day, preferably for 3-7 days, and may be combined with probiotics, prebiotics, minerals, vitamins, or plant extracts.

Source

Microbial-based therapies for treating neurological and metabolic disorders. The therapies involve administering a composition of isolated and purified microbes that increase production of butyrate in the subject. The microbes can be selected based on their ability to modulate nervous system receptors, neurotransmitters, and metabolic pathways. The composition can be formulated as an oral capsule or pill.

Source

Compositions containing specific bacterial isolates for preventing, treating, or inhibiting diseases. The compositions comprise isolated bacteria strains from the genera Bacteroides, Odoribacter, Parabacteroides, Paraprevotella, Coprococcus, Acidaminococcus, and Bifidobacterium. These bacteria strains can be provided to subjects to prevent, treat, or inhibit diseases where the subject lacks or has reduced amounts of these bacteria. The compositions can contain prebiotics, stabilizers, antibacterial agents, antifungal agents, preservatives, and media components. The bacteria can be lyophilized, spray dried, or freeze dried, and inactivated if desired. The compositions can be formulated as powders, liquids, capsules, caplets, sprays, or foods for oral delivery.

Source

Use of Lactobacillus paracasei subsp. paracasei K56 (CGMCC 15139 or DSM 27447) for alleviating intestinal inflammation, characterized by reducing inflammatory factors IL-6 and TNF-α, promoting anti-inflammatory factor IL-10, and reducing tissue damage in colitis.

Source

Compositions and methods for alleviating gastrointestinal symptoms in subjects with neurological disorders, comprising a blend of non-pathogenic bacterial strains, such as Lactobacillus casei and Bifidobacterium longum, that disrupt biofilms and improve gut physiology. The compositions can also include enzymes that break down fiber and disrupt biofilms, and are particularly effective in reducing Delftia populations in the gut.

Source

Composition of probiotic bacteria for increasing resilience against infection by pathogenic bacteria like ETEC in young mammals like piglets. The composition is administered pre-weaning to help the piglets overcome pathogen challenges post-weaning. The early probiotic intervention improves intestinal microbial colonization, maturity of immune systems, and tolerance to infection. The composition contains specific strains like Lactobacillus, Lacticaseibacillus, Bacillus, and Bifidobacterium.

Source

Using sophorolipids to improve animal health and performance by modulating the gut microflora. Sophorolipids are naturally occurring compounds produced by certain yeast strains. They are used in animal feed to alleviate coccidiosis and diseases caused by clostridium sp. The sophorolipids are added to the feed to improve gut health and reduce inflammation.

Source

Novel bacterial strains for treating gastrointestinal disorders, including irritable bowel syndrome (IBS), comprising Bifidobacterium breve BbIBS01, Bifidobacterium breve BbIBS02, Bifidobacterium animalis subsp. lactis BlIBS01, and Lactobacillus plantarum LpIBS01. The strains are effective in preventing and treating IBS symptoms, including abdominal pain, changes in bowel habits, and altered defecation patterns. The strains can be used alone or in combination with other probiotics, such as Lactobacillus casei DG and Lactobacillus paracasei LPC-S01, to provide comprehensive gut health benefits.

Source

A strain of the lactic acid bacteria species Lacticaseibacillus paracasei (L. paracasei) called EM205-11. The strain has probiotic properties, such as adhering to intestinal cells without invading them, improving gut barrier function, and having anti-inflammatory effects. It also has a broad ability to utilize prebiotic carbohydrates like inulin. Compositions containing this strain, supernatants, extracts, or derivatives are provided for improving gut health, treating inflammatory disorders, preventing leaky gut, and promoting intestinal barrier function.

Source

Use of Bifidobacterium lactis BL-99 (deposit number CGMCC 15650) for suppressing intestinal inflammation, comprising administering an effective amount of the bacterium to a subject, either in viable or dead form, to reduce inflammatory factors IL-6 and/or TNF-α, promote anti-inflammatory factor IL-10, and alleviate tissue damage in colitis.

Source

Compositions containing yeast, such as Cyberlindnera jadinii and Kluyveromyces lactis, for treating and preventing gastrointestinal inflammation and associated diseases, including inflammatory bowel disease, cancer, and metabolic disorders. The yeast compositions can be administered orally in various forms, including tablets, capsules, and powders, and can provide long-lasting protective effects through intestinal colonization.

Source